RxDoctor Payments DataLook up a doctor →

Steven Bauer

Family Medicine · Charlotte, NCNPI 1053402875

Payments from drug & device makers

$2,742,033in general payments, 2019–2025

Across 1,666 payments — averaging $1645.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$915K
  • Pfizer$433K
  • Novo Nordisk AS$353K
  • AbbVie$302K
  • Amgen$146K
  • AstraZeneca$124K
  • plus $469K from 54 others
$73,670in research payments, 2019–2025

Across 25 payments — averaging $2946.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Orexo US, Inc.$42K
  • Pfizer$31K
  • AbbVie$1000

What the payments were for

  • Speaking & faculty fees$4002%
  • Travel & lodging$2,11310%
  • Food & beverage$19,62688%
  • Education$790%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Modernatx, Inc.99$915,018
Pfizer103$432,659
Novo Nordisk AS136$352,609
AbbVie(2 entities)191$301,563
Amgen(2 entities)39$146,329
AstraZeneca82$124,462
Merck56$102,038
Otsuka Pharmaceutical Development & Commercialization, Inc.5$86,018
Cipla USA Inc.25$56,210
Biohaven Pharmaceutical Holding Company Ltd.31$41,538
Incyte Corporation107$38,112
Genentech, Inc.11$37,740
Sanofi US Services Inc.6$23,478
GSK18$22,201
Indivior Inc.10$15,824
Evofem Biosciences, Inc.11$10,571
Biohaven Pharmaceuticals, Inc.16$8,549
Regeneron1$7,500
Janssen Research & Development, LLC3$6,311
Novo Nordisk155$2,876
Lilly USA, LLC60$838
Bausch Health US, LLC55$743
Boehringer Ingelheim33$621
Johnson & Johnson(2 entities)37$605
Amarin Pharma, Inc.36$539
Aytu Biopharma, Inc.11$516
Antares Pharma, Inc.21$436
Bayer19$424
Novartis19$404
Esperion Therapeutics, Inc.12$331
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC19$314
Takeda Pharmaceuticals U.S.A., Inc.19$282
Eisai Inc.12$281
Sumitomo Pharma America, Inc.10$234
Abbott11$232
Exact Sciences12$218
Theratechnologies Inc.8$194
Paratek Pharmaceuticals, Inc.6$182
Medtronic(2 entities)2$181
Kowa Pharmaceuticals America, Inc.11$167
Neos Therapeutics, LP11$152
Almatica Pharma LLC7$150
Astellas Pharma US Inc7$142
GRT US Holding, Inc.3$136
Clarus Therapeutics Inc.8$132
Arbor Pharmaceuticals, Inc.8$129
Sanofi-aventis U.S. LLC6$117
Gilead5$108
Verity Pharmaceuticals Inc.4$99
Orexo US, Inc.6$98
Tolmar, Inc.5$83
Genentech USA, Inc.5$76
Azurity Pharmaceuticals, Inc.4$76
Amneal Pharmaceuticals LLC4$68
MDD US Operations, LLC4$63
Hikma Pharmaceuticals USA3$62
Acella Pharmaceuticals, LLC4$60
Idorsia Pharmaceuticals US Inc3$56
IBSA Pharma Inc.3$52
Alfasigma USA, Inc.2$49

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,742,033 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$147,315
Medicare patients
296
Services billed
2,848

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol82$82,187
OzempicSemaglutide55$72,107
JardianceEmpagliflozin51$58,521
EliquisApixaban35$40,045
VascepaIcosapent Ethyl19$18,713
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$15,509
XareltoRivaroxaban12$11,901
Atorvastatin Calcium279$2,738
Ezetimibe116$2,296
Rosuvastatin Calcium188$2,174
Levothyroxine Sodium166$2,099
SynthroidLevothyroxine Sodium31$2,066
Omeprazole91$2,032
Valsartan72$1,861
Gabapentin48$1,611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$124,462$82,18782 claims
Novo NordiskOzempic$2,876$72,10755 claims
Boehringer IngelheimJardiance$621$58,52151 claims
PfizerEliquis$432,659$40,04535 claims
GSKTrelegy Ellipta$22,201$15,50911 claims
Johnson & JohnsonXarelto$605$11,90112 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$68$2,099166 claims
AbbVieSynthroid$301,563$2,06631 claims
Hikma Pharmaceuticals USABuprenorphine$62$1,45213 claims
Almatica Pharma LLCSertraline Hcl$150$57558 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →